相关临床试验
12
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2016
进行中（未招募）
3
25.0%
已完成
1
8.3%
招募中
2
16.7%
终止
6
50.0%
暂无批准数据
- A July 2026 survey of 92 neurologists found 77% believe CAR T therapies could make current standards of care obsolete in neuro-immune diseases if proven safe and effective. - Safety is the clearest adoption barrier, with 74% of neurologists citing the safety profile as a major concern, including cytokine release syndrome and neurotoxicity. - Cartesian Therapeutics' Descartes-08 (BCMA-directed) and Kyverna's miv-cel (anti-CD19) lead physician familiarity among investigational CAR T programs. - Neurologists expect initial delivery through academic centers and shared-care models with hematologist-oncologists, making logistics central to uptake.
- Multiomic profiling of atherosclerotic plaques and peripheral circulation identified 15 proteins linked to disease symptomatology, including novel markers PCOLCE, FUT5, and ICOSLG, with ANGPTL3 tied to adverse cardiac events. - Researchers at Mount Sinai discovered shared Th2 protein dysregulation among major depressive disorder, psoriasis, and atopic dermatitis, suggesting dupilumab could be repurposed for MDD via an in silico druggability approach. - Cartesian Therapeutics' phase 2b trial of Descartes-08, an mRNA CAR-T cell therapy for myasthenia gravis, demonstrated precision immune reset without unwanted inflammation, with durable reductions in IL-6, CCL19, and other autoimmune markers. - Eli Lilly's post hoc analysis of the AWARD-7 trial using a custom 21-protein Joslin Kidney Panel revealed dulaglutide's kidney-protective effects are conditional on baseline clinical variables like eGFR, enabling patient stratification.
- The FDA cleared an Investigational New Drug (IND) application for MMA-101, an adeno-associated virus (AAV)-based gene therapy candidate for patients with methylmalonyl-CoA mutase (MMUT) methylmalonic acidemia, a rare pediatric metabolic disease with no approved treatments. - The IND clearance allows a first-in-human Phase I/II clinical trial to move forward at the NIH Clinical Center, sponsored by the National Human Genome Research Institute in collaboration with NCATS and several NIH partners. - The program represents a unique effort to revive and develop a rare disease therapy after Selecta Biosciences discontinued its MMA gene therapy program in 2023 due to commercial constraints and donated the manufactured drug product to NIH. - MMA-101 is designed to deliver a functional copy of the human MMUT gene to the liver using a serotype-8 AAV vector, potentially restoring MMUT enzyme activity without the risks associated with liver transplantation and lifelong immunosuppression.
- DelveInsight's 2026 pipeline analysis reveals over 50 companies actively developing more than 50 investigational therapies for acute respiratory distress syndrome treatment. - Leading drug candidates include STSA-1002 (complement C5a inhibitor), GEn 1124 (MAPK14 inhibitor), and ALT-100 (eNAMPT inhibitor), spanning various mechanisms of action and development stages. - Recent clinical milestones include Edesa Biotech's positive Phase III results for paridiprubart and FDA Fast Track designations for multiple ARDS therapies. - The pipeline demonstrates significant therapeutic diversity with approximately 20 drugs in mid-stage development and 22 in early-stage trials.
- Cartesian Therapeutics received FDA acceptance for its IND application to initiate a Phase 2 trial of Descartes-08 in myositis, with potential for a single pivotal trial starting in the first half of 2026. - The company's Phase 3 AURORA trial of Descartes-08 in myasthenia gravis remains on track, with the therapy recently named to Nature Medicine's list of eleven clinical trials that will shape medicine in 2026. - New Nature Medicine publications revealed that Descartes-08 achieved precision retuning of autoreactivity and demonstrated deep, durable responses through 12 months, with 57% of biologic-naive patients achieving minimal symptom expression. - The company initiated a Phase 1/2 pediatric trial for juvenile dermatomyositis and expects current cash resources to support operations through mid-2027.
- A phase 2b randomized controlled trial of Descartes-08, an mRNA-based CAR-T cell therapy targeting BCMA, demonstrated significant clinical benefits in patients with generalized myasthenia gravis. - The therapy achieved minimal symptom expression in 57% of participants by month six, with sustained benefits maintained through twelve months after treatment. - Unlike traditional CAR-T therapies, Descartes-08 preserved global immune function while selectively targeting pathogenic plasma cells and plasmacytoid dendritic cells. - The treatment represents a potential breakthrough as an outpatient, first-line therapy for myasthenia gravis and other autoimmune diseases.
- Cartesian Therapeutics has appointed Adrian Bot, M.D., Ph.D., a veteran biopharma executive with three decades of R&D experience, to its Board of Directors. - Dr. Bot brings extensive expertise in CAR-T cell therapies, having contributed to first-in-class cancer treatments at Kite Pharma and founding Capstan Therapeutics. - The appointment comes as Cartesian advances its lead asset Descartes-08, a CAR-T therapy in Phase 3 trials for generalized myasthenia gravis. - Dr. Bot will serve on the Science and Technology Committee as the company explores opportunities beyond ex-vivo cell therapy.
- MBX Biosciences shares jumped 33% after-hours ahead of Phase 2 topline results for Canvuparatide, a once-weekly therapy for chronic hypoparathyroidism, scheduled for release on Monday. - Structure Therapeutics gained 11.37% in extended trading as attention builds around its obesity drug aleniglipron, with Phase 2b trial results expected by end of 2025. - Multiple biotech companies including Cartesian Therapeutics, Rapport Therapeutics, and Rezolute saw significant after-hours gains driven by upcoming clinical milestones and positive trial developments. - The rally reflects strong investor appetite for clinical-stage biotechnology companies with near-term data catalysts and promising pipeline assets.
- The FDA approved nipocalimab (Imaavy) in May 2025 as the first therapy targeting the underlying cause of generalized myasthenia gravis in patients aged 12 and older with specific antibodies. - Over 20 companies are developing 22+ novel myasthenia gravis therapies, including promising candidates like Descartes-08, Telitacicept, and batoclimab showing sustained efficacy in Phase 2b and Phase 3 trials. - Recent clinical developments include Cartesian Therapeutics reporting 12-month sustained improvement with Descartes-08 and RemeGen sharing positive Phase 3 results for Telitacicept at the 2025 AAN Annual Meeting.
- The myasthenia gravis market across seven major markets is projected to grow from $6.1 billion in 2024 to $10.3 billion by 2034, representing a 5.3% compound annual growth rate. - Seven late-stage pipeline products including CRD-1, Descartes-08, Imaavy, gefurulimab, inebilizumab, pozelimab + cemdisiran combination therapy, and telitacicept are expected to drive market expansion. - The combination therapy of pozelimab and cemdisiran shows particular promise for treating seronegative myasthenia gravis patients, addressing a significant unmet medical need. - Despite growth potential, generic erosion and biosimilar competition pose barriers, particularly affecting high-grossing disease-modifying therapies that generated an estimated $5 billion in combined sales in 2024.
